|Year : 2020 | Volume
| Issue : 6 | Page : 846-851
Ten years of strong opioid analgesics consumption in Malaysia and other Southeast Asian countries
Che Suraya Zin
Kulliyyah of Pharmacy, International Islamic University Malaysia, Kuantan, Pahang, Malaysia
|Date of Submission||03-Nov-2019|
|Date of Decision||07-Jun-2020|
|Date of Acceptance||16-Aug-2020|
|Date of Web Publication||05-Nov-2020|
Dr. Che Suraya Zin
Kulliyyah of Pharmacy, International Islamic University Malaysia, Kuantan Campus, Kuantan, Pahang.
Source of Support: None, Conflict of Interest: None
| Abstract|| |
Background: It was reported that opioid consumption in developing countries was stagnated or decreased, but precise data on the consumption are unclear. This study examined the trends and patterns of opioid consumption in Malaysia and other four Southeast Asian countries. Materials and Methods: Data of five strong opioids consumption (morphine, oxycodone, fentanyl, pethidine, and methadone) between 2005 and 2014 from Malaysia, Singapore, Indonesia, Thailand, and Vietnam were extracted from the Pain and Policy Studies Group. Defined daily doses per 1000 inhabitants per day (DDD/1000 inhabitants/day) was used for calculating the annual amount of opioid use. Results: The total consumption of five strong opioids was increased in all five Southeast Asian countries during a 10-year study period. Malaysia was recorded with the largest increase of the opioid consumption (993.18%), followed by Indonesia (530.34%), Vietnam (170.17%), Singapore (116.16%), and Thailand (104.66%). Malaysia also had the highest total strong opioid consumption (11.2 DDD/1000 inhabitants/day), primarily for methadone. Among the opioids used for pain management, fentanyl was primarily used in Malaysia and Singapore but the greatest increase in these two countries was for oxycodone. Fentanyl was also primarily used in Indonesia while morphine was predominantly used in Thailand and Vietnam. Conclusion: Growing trends of strong opioids consumption in all five Southeast Asian countries demonstrated in this study may indicate improved access to opioid analgesics in these countries. Given the increasing trends, it is important to ensure that the utilization of opioids is according to the guideline to prevent the negative consequences of opioids particularly when used in chronic non-cancer pain.
Keywords: Consumption, Malaysia, Southeast Asian countries, strong opioids, trends
|How to cite this article:|
Zin CS. Ten years of strong opioid analgesics consumption in Malaysia and other Southeast Asian countries. J Pharm Bioall Sci 2020;12, Suppl S2:846-51
|How to cite this URL:|
Zin CS. Ten years of strong opioid analgesics consumption in Malaysia and other Southeast Asian countries. J Pharm Bioall Sci [serial online] 2020 [cited 2020 Nov 24];12, Suppl S2:846-51. Available from: https://www.jpbsonline.org/text.asp?2020/12/6/846/299980
| Introduction|| |
Opioid analgesics such as fentanyl, oxycodone, and morphine have long been used for the treatment of pain. The World Health Organization considers the annual morphine consumption in each country as an indicator of access to opioids for pain management and the consumption of morphine has been regarded as a gold standard in the treatment of moderate to severe cancer pain., Morphine has also been included in the list of Essential Medicines to recognize the significance of morphine for improving patients’ health status and well-being.
There have been large inequalities between high-income countries and low- and middle-income countries (LMICs) in the global opioid consumption. It was reported that high-income countries which constituted 17% of the world’s population consumed almost all of the global opioid consumption (92%), whereas only 8% of the global consumption of opioids was attributed to the LMICs which constituted 83% of the world’s population., The imbalance of the global opioid consumption is likely to reflect inadequate pain management in the LMICs.
Although it was reported that the opioid consumption in the LMICs was stagnated or decreased, precise data on the consumption are unclear. Therefore, the current study was prompted to examine the trends of strong opioid consumption in Malaysia and other four Southeast Asian countries, which include Singapore, Indonesia, Thailand, and Vietnam. The inclusion of only these five countries and not all countries in the region is to provide in-depth data on strong opioid consumption from the individual country’s perspective rather than regional superficial data if all the countries were included. The in-depth data can serve as an indicator to assess the readiness for the treatment of moderate-to-severe pain.
| Materials and Methods|| |
Study design and data source
This study was a retrospective cross-sectional study that evaluated the consumption of strong opioids in five Southeast Asian countries (Malaysia, Singapore, Indonesia, Thailand, and Vietnam). Data of all available strong opioids (morphine, oxycodone, fentanyl, pethidine, and methadone) between 2005 and 2014 for the five countries were extracted from the Pain and Policy Studies Group (PPSG). The PPSG is the WHO Collaborating Centre for Pain Policy and Palliative Care that directly obtains data on opioid consumption from the International Narcotics Control Board (INCB) annually. The latest data was only available up to 2014 at the time of data extraction from the PPSG.
Defined daily dose (DDD) is the assumed average maintenance dose per day for a drug used for its main indication in adults. Given the present data, DDD per 1000 inhabitants per day (DDD/1000 inhabitants/day) is the most appropriate tool for comparing the consumption of opioid for each country. The reported amount of opioid from the PPSG in mg per capita were converted to DDD/1000 inhabitants/day by dividing the amount by its relevant DDD and then multiplied by 1000. This value was then divided by 365 to derive DDD/1000 inhabitants/day.
The DDDs used in the present study was according to a report published by the WHO Collaborating Centre for Drug Statistics Methodology, Anatomical Therapeutic Chemical Classification System (ATC classification index) 2018. The DDDs used in the current study were morphine (100 mg), fentanyl (transdermal) (1.2 mg), oxycodone (75 mg), and pethidine (400 mg). The DDD for methadone was 25 mg, an amount used in the methadone treatment for opioid dependence. The amount was used in the present study due to unavailability of DDD for analgesic use of methadone.
The total consumption of all five strong opioids with methadone and without methadone was calculated annually to differentiate the use of opioids for opioid dependence and pain management. The total consumption of each of the strong opioid (fentanyl, morphine, methadone, oxycodone, and pethidine) in each country for each year was also characterized. However, data for oxycodone in Indonesia, Thailand, and Vietnam were not available.
Descriptive statistics were used to report the annual opioid consumption in each year. The percentage change in the annual consumption between 2005 and 2014 for each opioid in each country was also calculated. All analyses were performed using Stata/SE 15. 1.
| Results|| |
Total strong opioid consumption in five Southeast Asian countries with and without methadone
Over a 10-year study period, the total strong opioid consumption with methadone was increased in all five Southeast Asian countries. Malaysia recorded the largest increase of strong opioid consumption (993.18% increase), followed by Indonesia (530.34% increase), Vietnam (170.17% increase), Singapore (116.16% increase), and Thailand (104.66% increase) [Table 1]. During the study period, the total overall opioid consumption with methadone in Malaysia was higher (11.204 DDD/1000 inhabitants/day) than that of Vietnam (0.244), Singapore (1.786), Thailand (0.971), and Indonesia (0.371).
|Table 1: Consumption of strong opioids between 2005 and 2014 in DDD per 1000 inhabitants per day in Southeast Asian countries|
Click here to view
From 2005 to 2014, the total consumption of four opioids without methadone (fentanyl, morphine, oxycodone, and pethidine) was increased in all five countries. Indonesia recorded the largest increase (591.67% increase), followed by Vietnam (198.23% increase), Singapore (121.06% increase), Thailand (120.0% increase), and Malaysia (47.23% increase). During the same period, the total consumption of the four opioids was the highest in Singapore (1.73 DDD/1000 inhabitants/day), followed by Malaysia (1.043), Thailand (0.545), Vietnam (0.208), and Indonesia (0.075).
Over the 10-year study period, the consumption of methadone increased the largest in Malaysia (1884.58% increase) compared with Indonesia (451.39% increase), Thailand (87.55% increase), Vietnam (68.98% increase), and Singapore (12.73% increase) [Table 1]. The consumption of methadone was the highest in Malaysia (10.161 DDD/1000 inhabitants/day), followed by Thailand (0.426), Indonesia (0.296), Singapore (0.056), and Vietnam (0.036). Ninety percent of the total opioid consumption in Malaysia was contributed by the consumption of methadone (10.161 DDD/1000 inhabitants/day), which was mainly used in opioid dependence programs.
Consumption of fentanyl, oxycodone, morphine, and pethidine
Among the opioids used for pain management in Malaysia, fentanyl was predominantly used (0.431 DDD/1000 inhabitants/day) followed by morphine (0.287), pethidine (0.222) and oxycodone (0.103) during the 10-year study period. The consumption of oxycodone (143.29%) was increased at a higher rate than that of fentanyl (128.61%). In contrast, there was a decrease in the consumption of morphine (–19.91% decrease) and pethidine (–14.30% decrease) [Figure 1].
|Figure 1: Total consumption of oxycodone, morphine, fentanyl, and pethidine in each Southeast Asian country|
Click here to view
Fentanyl (0.041 DDD/1000 inhabitants/day) had the highest consumption in Indonesia followed by pethidine (0.018) and morphine (0.016). The increase in the consumption was the largest for fentanyl (1480.81% increase), followed by morphine (340.78% increase) and pethidine (167.19% increase).
Fentanyl was also the most commonly used opioid (1.08 DDD/1000 inhabitants/day) in Singapore, followed by morphine (0.311), oxycodone (0.186), and pethidine (0.153) during the same study period. The consumption of oxycodone (4116.24% increase) and fentanyl (196.31% increase) was increased while a decrease was noted in the consumption of morphine (-27.02% decrease) and pethidine (–42.30% decrease).
In Thailand, morphine was the most commonly used opioid during the study period (0.257 DDD/1000 inhabitants/day) followed by fentanyl (0.217) and pethidine (0.071). An increase was noted in the consumption of fentanyl (254.81% increase) and morphine (121.63% increase), whereas the utilization of pethidine decreased (–32.41% decrease).
Morphine (0.093 DDD/1000inhabitants/day) appeared to be consumed the most in Vietnam compared with fentanyl (0.083) and pethidine (0.032). Fentanyl recorded the largest increase in utilization (290.63% increase), followed by morphine (204.60% increase) and pethidine (68.98% increase).
| Discussion|| |
Over a 10-year study period, the total consumption of five strong opioids increased in all of the five Southeast Asian countries. Malaysia was noted with the largest increase in the consumption over time as well as the highest total consumption of the five strong opioids, primarily for methadone. As for the consumption of opioids that are mainly used for pain management (fentanyl, morphine, oxycodone, and pethidine), Singapore was recorded with the highest total consumption but the largest increase was noted for Indonesia.
The present study showed that the trends of opioids consumption in all of the five Southeast Asian countries increased over time despite the usage being lower than global average. This increasing trend is a positive direction that reflects the improvement in the availability of opioid analgesics in all the five countries. This direction is the first requirement for addressing further the issue of inadequacy of opioid analgesics in most of the countries. To further improve the access to opioids, collaborative efforts from relevant departments such as by governments, non-governmental organizations, and health organizations are required. Although the opioid consumption is very regional in nature and the drivers of changes are different by countries, the focus in general should be directed on educational, cultural measures, regulatory enforcement, and health policy development.
Among the opioids for pain management, fentanyl was the most frequently used in Malaysia, although the greatest increase was marked for oxycodone. A similar trend of consumption was also seen in Singapore. Fentanyl and morphine in Malaysia are recommended for treating cancer pain and the availability of a new formulation of fentanyl transdermal patch may explain the preference to choose for fentanyl to morphine. The increasing use of oxycodone and the decreasing use of morphine as shown in the current study for Malaysia and Singapore were also seen in other countries such as Denmark, United Kingdom, and Nordic countries.,, A previous study that evaluated the dose and duration of opioids at a tertiary hospital setting in Malaysia demonstrated a similar finding; the increasing use of oxycodone which was mainly used for non-cancer pain. This finding reflects that the higher cost of oxycodone compared with morphine does not discourage the prescribers from prescribing oxycodone. Factors other than clinical and economic evidence could influence the choice of opioid, such as the convenience of dosing, availability of new formulations, anticipated adverse effects, and doctor or patient preferences.
The current study also demonstrated that Indonesia used fentanyl the most while Thailand and Vietnam primarily used morphine. It is also noted that no data for oxycodone were available in these countries. The overall strong opioids consumption in these countries was low and their main utilization of fentanyl and morphine may reflect the usage was mainly for cancer pain, and limited for non-cancer pain. Moreover, lack of studies was found on the usage of opioids on non-cancer pain from the three countries. The consumption of pethidine was little in all countries and was decreased in Malaysia, Singapore, and Vietnam which may reflect the replacement of pethidine by other opioids due to the former’s accumulation of a toxic metabolite and inappropriateness for the treatment of chronic pain.
The data on opioid consumption between the countries should be interpreted with caution due to the variability in methods of collecting and reporting the data. For the data from INCB as used in the current study, the result might be incomplete or invalid for a particular year because some governments have issued inaccurate reports, have delayed the reporting or have not reported for a particular year or period. The consumption data also do not distinguish among clinical uses of opioids and whether the opioids have been used by hospitals or other institutions. The information on dosage forms of an opioid or the availability of which products in a country are also not captured when using the opioid consumption data.
| Conclusion|| |
The overall increasing trends of strong opioids consumption in all five Southeast Asian countries may reflect the improvement in the access to opioid analgesics. Malaysia had the largest increase as well as the highest total of strong opioid consumption during the study period, primarily for methadone. Among the opioids for pain management, fentanyl was primarily used in Malaysia, Singapore, and Indonesia while the use of morphine predominates in Thailand and Vietnam. Given the positive trend of the consumption, it is important to ensure that the utilization of opioids is according to the guideline to prevent the negative consequences of opioids particularly when used in chronic non-cancer pain.
CSZ was supported by a fundamental research grant scheme from the Ministry of Higher Education Malaysia (FRGS 19-010-0618). CSZ initiated and developed the research questions and study design, conducted data management and analysis, drafted the manuscript and revised the ﬁnal version submitted for publication.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Foley K, Wagner J, Joranson D, Gelband H Pain control for people with cancer and AIDS. In: Jamison D, Breman J, Measham A, Alleyne G, Claeson M, Evans D, et al
, editors. Disease control priorities in developing countries. New York: Oxford University Press; 2006. p. 981-93.
World Health Organization. Cancer pain relief. Geneva, Switzerland World Health Organization; 1986. [Internet]. Available from: http://apps.who.int/iris/bitstream/10665/43944/1/9241561009_eng.pdf. [Last accessed on 2018 Feb 18].
World Health Organization. Cancer pain relief: with a guide to opioid availability. Geneva, Switzerland: World Health Organization; 1996. Available from: http://apps.who.int/iris/bitstream/10665/37896/1/9241544821.pdf. [Last accessed on 2018 Feb 18].
World Health Organization. World Health Organization Essential Medicines Library, Morphine. 2011. [Internet]. Available from: http://apps.who.int/iris/bitstream/10665/70640/1/a95053_eng.pdf. [Last accessed on 2018 Feb 18].
Gilson AM, Maurer MA, Ryan KM, Rathouz PJ, Cleary JF Using a morphine equivalence metric to quantify opioid consumption: examining the capacity to provide effective treatment of debilitating pain at the global, regional, and country levels. J Pain Symptom Manage 2013;45:681-700.
Report of the International Narcotics Control Board for 2016 [Internet]. New York; 2017. Available from: https://www.incb.org/documents/Publications/AnnualReports/AR2016/English/AR2016_E_ebook.pdf. [Last accessed on 2018 Feb 18].
Hastie BA, Gilson AM, Maurer MA, Cleary JF An examination of global and regional Opioid consumption trends 1980–2011. J Pain Palliat Care Pharmacother 2014;28: 259-75.
Bosnjak S, Maurer MA, Ryan KM, Leon MX, Madiye G Improving the availability and accessibility of opioids for the treatment of pain: the international pain policy fellowship. Support Care Cancer 2011;19:1239-47.
Pain & Policy Studies Group. Improving global pain relief by achieving balanced access to opioids worldwide. University of Wisconsin-Madison [Internet]. [cited February 19, 2018]. Available from: http://www.painpolicy.wisc.edu/. [Last accessed on 2019 Aug 15].
ATC/DDD Index 2018. WHO Collaborating Centre for Drug Statistics Methodology [Internet]. 2018. Available from: https://www.whocc.no/atc_ddd_index/. [Last accessed on 2018 Feb 18].
Duthey B, Scholten W Adequacy of opioid analgesic consumption at country, global, and regional levels in 2010, its relationship with development level, and changes compared with 2006. J Pain Symptom Manage 2014;47: 283-97.
World Health Organization. Achieving balance in national opioids control policy: guidelines for assessment. Geneva, Switzerland: World Health Organization [Internet]. 2000 [cited February 19, 2018]. Available from: http://apps.who.int/medicinedocs/pdf/whozip39e/whozip39e.pdf. [Last accessed on 2019 Aug 15].
Zin CS, Chen LC, Knaggs RD Changes in trends and pattern of strong opioid prescribing in primary care. Eur J Pain 2014;18:1343-51.
Poulsen KK, Andersen SE, Moreno SI, Glintborg D, Thirstrup S, Aagaard L General practitioners’ and hospital physicians’ preference for morphine or oxycodone as first-time choice for a strong opioid: a national register-based study. Basic Clin Pharmacol Toxicol 2013;112:110-5.
Hamunen K, Paakkari P, Kalso E Trends in opioid consumption in the Nordic countries 2002-2006. Eur J Pain 2009;13:954-62.
Zin CS, Rahman NA, Ismail CR, Choy LW Dose and duration of opioid use in patients with cancer and noncancer pain at an outpatient hospital setting in Malaysia. Pain Pract 2017;17:774-81.
Javier FO, Irawan C, Mansor MB, Sriraj W, Tan KH, Thinh DHQ Cancer pain management insights and reality in Southeast Asia: expert perspectives from six countries. J Glob Oncol 2016;2:235-43.
Krakauer EL, Nguyen TP, Husain SA, Nguyen TH, Joranson DE, Luong NK, et al
. Toward safe accessibility of opioid pain medicines in Vietnam and other developing countries: a balanced policy method. J Pain Symptom Manage 2015;49:916-22.
Fallon M, Cherny N, Hanks G Opioid analgesic therapy. In: Hanks G, Cherny N, Christakis N, Fallon M, Kaasa S, Portenoy R, editors. Oxford textbook of palliative medicine. 4th ed. New York: Oxford University Press; 2010. p. 661-8.
Hamunen K, Laitinen-Parkkonen P, Paakkari P, Breivik H, Gordh T, Jensen NH, et al
. What do different databases tell about the use of opioids in seven European countries in 2002? Eur J Pain 2008;12:705-15.